Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 05 | Received 29.10.2026 | Accepted 3.11.2026 | Online 8.11.2026

TOPICAL CLOTRIMAZOLE 1% (CANDID) IN THE MANAGEMENT OF ACUTE PSEUDOMEMBRANOUS ORAL CANDIDIASIS IN NEONATES: CLINICAL EVIDENCE AND A PROSPECTIVE EVALUATION FRAMEWORK

Axtamova Moxinur Mustafo qizi
Department of Dentistry, Asia International University, Bukhara, Uzbekistan
ORCID: https://orcid.org/0009-0007-7342-1593 | Email: axtamovamohinur2@gmail.com

ABSTRACT

Acute pseudomembranous oral candidiasis is a frequent manifestation of mucosal Candida infection during early infancy, but neonatal-specific evidence for topical clotrimazole 1% solution, marketed in some settings as Candid, is limited. This article critically evaluates the clinical evidence relevant to its use and develops an outcome-oriented framework for prospective assessment in newborns. A targeted narrative synthesis was undertaken using neonatal case-series evidence, pediatric antifungal trials, contemporary clinical guidance, prescribing information and pharmacological safety assessments available through 14 November 2026. The most directly applicable study, a nonrandomized neonatal series, identified oral candidosis in 20 of 650 neonatal intensive-care admissions; 19 infants had a pseudomembranous phenotype. All 20 affected newborns received topical clotrimazole 1%, and visible lesions resolved within 2–6 days (median, 4 days); 12 infants were followed for three months without a documented recurrence. These observations are clinically encouraging but cannot establish comparative efficacy, because the treated group lacked an active-treatment control and the sample was small. Randomized studies of miconazole, nystatin and fluconazole in older infant populations support the importance of topical formulation and treatment adherence but do not directly quantify the effect of 1% clotrimazole in neonates. Differences in regional guidance, formulation excipients and neonatal vulnerability further limit extrapolation. A structured assessment of lesion clearance, feeding tolerance, recurrence, adverse events and product-specific exposure is proposed. Controlled neonatal studies with ethical oversight and locally authorized oral-mucosal formulations are required before definite conclusions regarding superiority or routine use can be drawn.

Keywords: neonatal oral candidiasis; pseudomembranous candidiasis; clotrimazole; Candid 1%; oral thrush; topical antifungal therapy; newborn safety; clinical effectiveness.

INTRODUCTION

Acute pseudomembranous candidiasis, commonly known as oral thrush, is characterized by adherent cream-white plaques on the tongue, buccal mucosa and other intraoral surfaces, sometimes leaving an erythematous surface after gentle removal. In newborns, it may

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 05 Received 29.10.2026 Accepted 3.11.2026 Online 8.11.2026

coexist with feeding discomfort, diaper dermatitis or antibiotic-associated disturbance of the developing microbiota. Candida colonization itself does not invariably indicate infection; diagnosis requires a compatible clinical phenotype and, in atypical or refractory cases, appropriate microbiological confirmation. The first weeks of life are clinically distinct from later infancy because of immunological immaturity, variable feeding capacity, limited drug-clearance capacity and the risks associated with preterm birth and neonatal intensive care [1,9,11,14].

The treatment objectives are not limited to the disappearance of visible plaques. Restoration of comfortable feeding, prevention of recurrence, avoidance of unnecessary systemic therapy and early identification of severe or invasive disease are equally important. Regional protocols differ: a 2025 Russian neonatal guideline identifies a 1% clotrimazole solution for topical application to oral mucosa in selected neonates with noninvasive infection, whereas other neonatal and pediatric guidance commonly prioritizes nystatin oral suspension for uncomplicated disease [2,10–13]. Consequently, topical clotrimazole should not be presented as a globally uniform first-line treatment or as an interchangeable substitute for any product labeled “clotrimazole 1%.”

Clotrimazole is an imidazole antifungal that impairs fungal ergosterol synthesis and thereby disturbs membrane function. Its antifungal mechanism is well characterized, but treatment outcomes depend on drug concentration at the mucosal surface, retention time, formulation and the susceptibility of the infecting organism [5]. The Candid 1% mouth-paint preparation described in registered product documentation contains clotrimazole with propylene glycol and glycerin as excipients; the precise commercial formulation and approved age range must be verified in the country of use [3,4]. Particularly in premature neonates, product-specific excipient exposure deserves attention rather than uncritical extrapolation from healthy older children or topical skin formulations [15].

The principal objective of this paper is to examine the direct clinical evidence for topical 1% clotrimazole in newborn oral thrush, interpret it alongside comparative pediatric antifungal trials, and formulate a clinically meaningful approach to prospective effectiveness and safety evaluation. The scientific contribution is an explicitly structured evidence-to-outcome framework, not a newly conducted trial or a claim of observed treatment success among the author’s own patients.

MATERIALS AND METHODS

This study was designed as a targeted narrative clinical evidence synthesis and methodological analysis. The evidence base was assembled from the primary neonatal report by Gupta and colleagues, published pediatric antifungal trials, a clinical evidence review, neonatal and infectious-disease treatment guidance, regional product labeling, and contemporary evidence concerning neonatal Candida infections and medication excipients [1–18]. Searches emphasized the combinations “neonate,” “oral thrush,” “acute pseudomembranous candidiasis,” “clotrimazole 1% solution,” “Candid mouth paint,” “nystatin,” “miconazole,” “fluconazole,” “neonatal safety” and “propylene glycol.” Sources were selected by clinical relevance and traceability, prioritizing evidence specific

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 05 Received 29.10.2026 Accepted 3.11.2026 Online 8.11.2026

to infants or newborns and distinguishing direct clotrimazole observations from trials of different antifungal agents.

For each identified clinical report, the study population, age category, sample size, treatment formulation, design, comparator, clinical-resolution outcome, follow-up, adverse-event reporting and principal sources of bias were extracted into an evidence matrix. Numerical findings were taken from the original publications; no retrospective patient dataset was constructed, no study-level effect size was pooled, and no inferential significance test was attributed to the present manuscript. The earliest neonatal clotrimazole cohort was treated as a prospective clinical observation without an antifungal comparator; its risk-factor case–control analysis was not misclassified as a randomized treatment trial [1]. Comparative cure estimates from subsequent infant trials were displayed only as contextual findings because they were obtained with other active molecules, in populations that were not restricted to newborns [6–8].

The original methodological component was a proposed five-domain clinical evaluation framework covering standardized lesion documentation, feeding function, short-term response, post-treatment recurrence and safety surveillance. The framework was designed to be compatible with future prospective studies, conditional upon local ethics approval and confirmation of legal authorization and formulation suitability for neonatal oral-mucosal use. No infant was enrolled, no treatment was administered for the preparation of this article, and therefore patient consent or research ethics authorization was not required for this literature-only analysis. The search was not registered, dual independent screening and formal risk-of-bias scoring were not undertaken, and the work is not represented as a systematic review or meta-analysis.

RESULTS

The most directly relevant evidence was a case–control investigation of hospitalized newborns published in 1996. Of 650 neonatal intensive-care admissions screened, 20 had oral candidosis; 19 of those cases were classified as acute pseudomembranous candidosis and one as the erythematous phenotype. All affected newborns received local clotrimazole 1% solution in the reported treatment course. Lesions resolved in all 20 treated infants, with a median clearance time of four days and a reported range of two to six days. Twelve newborns were available for three-month follow-up and none had documented recurrence. The accompanying risk-factor analysis identified birth asphyxia as the only statistically significant variable after multivariable adjustment, but that result concerns disease susceptibility rather than clotrimazole efficacy [1]. The absence of an active-treatment comparator, the small and clinically selected neonatal population and incomplete long-term follow-up mean that 20/20 resolution is an uncontrolled observed proportion rather than an estimate of superiority or expected effectiveness in general practice.

Table 1. Direct neonatal evidence on topical clotrimazole 1% from Gupta et al. (1996) [1].

Indicator	Published finding	Interpretive limitation
Neonates screened in NICU	650 admissions	Single clinical setting; not a population prevalence estimate.

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 05 Received 29.10.2026 Accepted 3.11.2026 Online 8.11.2026

Indicator	Published finding	Interpretive limitation
Oral candidosis detected	20/650 (3.1% calculated; article rounds to 3.2%)	Screening denominator differs from treatment cohort.
Acute pseudomembranous phenotype	19/20 affected neonates	One neonate had erythematous disease.
Clotrimazole formulation and exposure	Topical 1% solution in all 20 cases	No alternative antifungal arm.
Clinical lesion clearance	20/20; 2–6 days, median 4 days	No untreated/control estimate; spontaneous evolution cannot be separated.
Three-month recurrence assessment	0/12 relapsed among those followed	8/20 lacked documented long-term follow-up.




Figure 1. Descriptive endpoints in the published neonatal clotrimazole series [1]. The denominator for recurrence differs from the original treatment cohort; this figure must not be interpreted as randomized evidence.


The mechanistic evidence provides pharmacological plausibility for local clotrimazole treatment, yet pharmacology cannot replace outcomes research. Clotrimazole interrupts ergosterol biosynthesis; the resulting alteration of fungal membranes is relevant to Candida spp., but species susceptibility, frequency and duration of mucosal exposure, and the nature of the oral vehicle are determinants of observed response [5]. Product documentation confirms that Candid oral paint 1% is a defined oral-mucosal preparation, whereas products with the same active ingredient concentration may be intended for skin or other sites and cannot automatically be treated as interchangeable [3,4]. Regional neonatal treatment recommendations support a topical 1% clotrimazole formulation in selected circumstances, whereas a neonatal-unit guideline from New Zealand and guidance from Médecins Sans Frontières describe nystatin as an established alternative for uncomplicated neonatal oral thrush [2,10,12].

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 05 Received 29.10.2026 Accepted 3.11.2026 Online 8.11.2026

Table 2. Clinical evidence and applicability to neonates with pseudomembranous oral candidiasis.

Source / design	Published treatment finding	Applicability to Candid 1% in neonates
Gupta et al., 1996; neonatal series [1]	20/20 lesions cleared after topical 1% clotrimazole; median 4 days.	Directly relevant age and drug strength, but uncontrolled.
Hoppe et al., 1997; randomized infant study [6]	Miconazole vs nystatin cure: day 5, 84.7% vs 21.2%; day 12, 99.0% vs 54.1%.	Different agents; infant cohort not restricted to neonates.
Hoppe & Hahn, 1996; randomized infant study [7]	Day-14 cure: miconazole 85.1%; nystatin gels 42.8% and 48.5%.	Provides indirect formulation evidence only.
Goins et al., 2002; small infant randomized trial [8]	Fluconazole 15/15 vs nystatin 6/19 clinical cures.	Systemic vs topical comparison, not clotrimazole.
Russian neonatal guidance, 2025 [2]	Names 1% clotrimazole oral solution among local treatments.	Practice recommendation; evidence grade is low.
Other neonatal guidance [10,12]	Nystatin is described for uncomplicated oral thrush.	Demonstrates local protocol variation.

Other controlled infant trials show that topical formulation and therapeutic agent can influence the speed of visible clearance, although these comparisons do not establish the efficacy of the particular branded 1% clotrimazole solution. In a randomized study of immunocompetent infants by Hoppe and colleagues, clinical cure with miconazole oral gel was reported in 84.7% of patients by day five compared with 21.2% receiving nystatin suspension; at day twelve the proportions were 99.0% and 54.1%, respectively, using the per-protocol analysis [6]. An earlier multicenter study also favored miconazole over two nystatin gel products at day fourteen [7]. In a smaller trial by Goins and colleagues, fluconazole suspension achieved clinical cure in 15 of 15 infants versus six of 19 given nystatin, but the result must be interpreted against the small sample and differences in systemic treatment risk [8]. Figure 2 illustrates the first comparative trial only, with clear separation from the neonatal clotrimazole data.



Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 05 Received 29.10.2026 Accepted 3.11.2026 Online 8.11.2026

Figure 2. Clinical cure rates in an independent randomized infant trial of miconazole gel versus nystatin suspension [6]. These results are not Candid 1% efficacy estimates and do not permit a head-to-head ranking of clotrimazole against either drug.

Safety and case selection emerged as key reasons that effectiveness cannot be assessed solely by plaque disappearance. Some commercially registered 1% oral-paint solutions contain propylene glycol in the vehicle [3], for which regulatory safety reviews describe greater exposure-related vulnerability in very young infants, especially premature newborns [15]. It would be inappropriate to infer neonatal systemic safety from dermal absorption studies or to copy adult-oriented oral-label quantities into neonatal care without local product review. Additionally, clotrimazole lozenges or troches mentioned in international guidelines are dosage forms for patients able to dissolve them safely; they do not constitute a suitable neonatal administration method [9,13]. Unwell, febrile or poorly feeding neonates require broader assessment because localized thrush and invasive infection are clinically distinct entities [14,16].

Table 3. Formulation and safety considerations for proposed neonatal clinical research.

Domain	Assessment required	Reason
Product verification	Exact trade name, route, labeled oral-mucosal use and national authorization.	A 1% skin solution must not be substituted for an oral preparation.
Vehicle / excipients	Identify propylene glycol and other excipients, and evaluate exposure for gestational age.	Immature metabolism can alter safety margins in neonates [3,15].
Clinical status	Gestational age, birth weight, fever, feeding, hydration, systemic risk.	High-risk babies require differential assessment [14,16].
Local tolerability	Mucosal erythema, burning or irritation, vomiting, caregiver administration problems.	Safety should be documented beyond visible cure [3,4].
Follow-up	Persistence, recurrence, repeat antifungal prescriptions and caregiver adherence.	Short-term lesion clearance is not a durable effectiveness measure.

A proposed prospective assessment framework can correct weaknesses that limit interpretation of the available evidence. Eligible newborns would have clinically documented, localized pseudomembranous candidiasis and an explicit assessment of severe-disease red flags. Enrollment would require caregiver consent, neonatology oversight and use of products suitable and authorized for the specified age and route. A comparison with an established local standard treatment, such as nystatin when appropriate, could be considered only after ethical and regulatory review. Primary endpoints should focus on complete clinical lesion resolution at prespecified visits; secondary endpoints should measure feeding tolerance, time to improvement, recurrence, tolerability and mycological confirmation when clinically indicated. The study would require prospective sample-size justification and a prespecified analysis plan rather than using the historical 20-case series as an assumed effect-size guarantee.

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 05 Received 29.10.2026 Accepted 3.11.2026 Online 8.11.2026

Table 4. Proposed prespecified outcomes for future neonatal effectiveness studies (author-developed framework).

Endpoint	Operational definition	Evaluation safeguard
Primary clinical response	Complete disappearance of typical adherent plaques by a prespecified follow-up visit.	Standardized oral examination; blinded evaluator if feasible.
Time to improvement	Time from start of assigned therapy to documented reduction and clearance.	Use scheduled visits; avoid relying on recalled cure day.
Feeding and comfort	Change in feeding adequacy, refusal, discomfort and need for additional care.	Record baseline illness and feeding support.
Mycological status	Candida microscopy or culture in selected refractory or atypical cases.	Distinguish colonization from symptomatic infection.
Safety and tolerability	Local reactions, adverse events, feeding-related difficulties and formulation-specific risks.	Prespecified severity definitions and independent review.
Recurrence	Return of clinically confirmed lesions within a defined post-treatment interval.	Keep denominator, missing follow-up and rescue treatment transparent.




Figure 3. Proposed clinical safety and evaluation pathway for neonatal oral candidiasis, integrating disease severity, product verification and follow-up. Conceptual tool only; not a validated prescribing protocol.

4. DISCUSSION

Journal of Advances in Drug Research
ISSN: 2230-7761
www.jadr.co.in
Volume 17, Issue 05 Received 29.10.2026 Accepted 3.11.2026 Online 8.11.2026

The available neonatal observations provide a credible reason to investigate topical 1% clotrimazole in acute pseudomembranous candidiasis, but the evidence remains insufficient for a definitive efficacy claim. The direct series documented complete visible clearance within a relatively short interval among 20 treated newborns, suggesting that local clotrimazole can be associated with a favorable clinical course in a selected intensive-care population. Nevertheless, because all affected neonates received the same antifungal agent, natural resolution, differences in supportive measures, baseline severity and observer expectations cannot be separated from the drug effect. Moreover, only 12 of 20 treated infants had the reported three-month follow-up, limiting conclusions about recurrence [1]. Framing this descriptive series as a randomized trial or as proof that Candid 1% is superior to nystatin would materially overstate the evidence.

The comparative pediatric antifungal literature is informative for treatment principles, not for a direct brand-specific estimate. Infant trials demonstrate that miconazole oral gel and fluconazole suspension may produce higher observed cure proportions than nystatin in particular populations; however, the studied infants and administration systems differ from newborns receiving topical clotrimazole solution. A newborn cannot safely use a dissolving antifungal troche, and oral gel administration may have age-specific choking considerations, as reflected in published drug guidance [18], reinforcing the importance of product-route compatibility. Recommendations from international professional bodies should be interpreted with attention to patient age, disease severity, local licensing and the risk–benefit profile rather than translated into universal neonatal regimens [6–13].

A further limitation concerns the branded preparation itself. Candid 1% is not a generic guarantee of a standardized vehicle across every national market or manufacturer. Regulatory and product documents describe oral-mucosal clotrimazole formulations, but excipient exposure, local registration status and label wording may vary [3,4]. The European Medicines Agency has highlighted the limited capacity of newborns to metabolize certain excipients, including propylene glycol, under conditions of sufficient exposure [15]. This does not establish toxicity from any specific oral-paint dose; it shows why neonatologists and pharmacists must verify the precise formulation, quantity and repeated exposure before adopting a treatment protocol. The role of topical antimycotics in a well newborn with localized thrush must also be distinguished from the systemic antifungal management required for suspected invasive neonatal candidiasis [14,16].

Microbiological heterogeneity creates another reason to avoid overgeneralization. Gupta and colleagues cultured Candida albicans in approximately half of the affected neonates, while other Candida species were also detected [1]. Different organisms may vary in antifungal susceptibility, and prior azole exposure could influence the clinical course. The presence of a positive oral swab alone does not establish symptomatic infection, so a future trial should prioritize clinical phenotyping and reserve microbiological testing for situations where it improves diagnosis or changes management. Short-term clinical cure, feeding recovery and recurrence are distinct outcomes; they should be collected and interpreted separately rather than combined into an unsupported single “effectiveness percentage.”

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 05 | Received 29.10.2026 | Accepted 3.11.2026 | Online 8.11.2026

The proposed evaluation framework is designed to improve reproducibility and patient relevance. Its originality lies in the integrated requirement to verify the mucosal formulation and neonatal exposure, document initial lesion burden and feeding status, use prespecified follow-up windows, monitor adverse effects and report missing data transparently. If a future comparative study is undertaken, randomization and blinded outcome assessment, where feasible, would help distinguish treatment benefit from natural recovery or observer bias. Safety-sensitive groups such as very-low-birth-weight infants should not be incorporated into a standard uncomplicated-thrush protocol without separate specialist justification. An appropriate research programme would also consider caregiver usability, treatment costs and local antimicrobial stewardship rather than prioritizing the visible plaque score alone.

The limitations of the present article are inherent to targeted narrative evidence synthesis. It does not provide a comprehensive systematic search, pooled treatment estimates, a new neonatal cohort or patient-level safety data. Several randomized comparisons concern older infants and agents other than clotrimazole; one direct neonatal case series is historical and small. Guidance also reflects differing settings and regulatory systems, which limits immediate generalization to Uzbekistan. Therefore, the proposed framework is an informed research and clinical documentation model requiring prospective validation, not a validated treatment algorithm. More contemporary controlled neonatal data are needed to clarify whether 1% oral-mucosal clotrimazole delivers a favorable balance of lesion resolution, feeding recovery, tolerability and recurrence compared with an established local standard.

CONCLUSION

Topical 1% clotrimazole (Candid) has a biologically plausible antifungal mechanism and is supported by a small published neonatal case series in which oral lesions resolved after treatment; however, the absence of a comparative treatment arm prevents a definitive conclusion about its relative efficacy in acute pseudomembranous oral candidiasis. Evidence from randomized trials of other antifungal agents in infants is useful context but cannot be assigned to Candid 1% or extrapolated uncritically to the first 28 days of life. Clinical consideration of the preparation should depend on an explicitly oral-mucosal, locally authorized formulation and an individualized neonatal safety review. Prospective studies should report standardized plaque clearance, feeding outcomes, recurrence, formulation-specific adverse events and transparent denominators, with urgent specialist assessment for newborns with systemic warning signs. These steps would provide a stronger foundation for evaluating the clinical position of Candid 1% in neonatal care.

REFERENCES

1. Gupta P, Faridi MMA, Rawat S, Sharma P. Clinical profile and risk factors for oral candidosis in sick newborns. Indian Pediatr. 1996;33(4):299–303. PMID: 8772904. https://pubmed.ncbi.nlm.nih.gov/8772904/

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 05 | Received 29.10.2026 | Accepted 3.11.2026 | Online 8.11.2026

2. Ministry of Health of the Russian Federation. Neonatal Candidiasis: Clinical Recommendations. 2025; document ID 944_1. https://bazanpa.ru/minzdrav-rossii-klinicheskie-rekomendatsii-ot01012025-h6865185/
3. Glenmark Pharmaceuticals (Malaysia). Candid Mouth Paint 1% (clotrimazole): Registered Product Information. Revised August 9, 2021. https://quest3plus.bpfk.gov.my/front-end/attachment/4272/pharma/230937/V_54653_20210927_152709_D3.PDF
4. Candid 1% Solution for Local Use (Clotrimazole). Patient Information Leaflet, registration LP-No. (000553)-(RG-RU)-070222. https://stomatitu.net/media/docs/leaflet.pdf
5. Crowley PD, Gallagher HC. Clotrimazole as a pharmaceutical: past, present and future. J Appl Microbiol. 2014;117(3):611–617. doi:10.1111/jam.12554.
6. Hoppe JE; Antifungals Study Group. Treatment of oropharyngeal candidiasis in immunocompetent infants: a randomized multicenter study of miconazole gel vs nystatin suspension. Pediatr Infect Dis J. 1997;16(3):288–293. doi:10.1097/00006454-199703000-00007.
7. Hoppe JE, Hahn H. Randomized comparison of two nystatin oral gels with miconazole oral gel for treatment of oral thrush in infants. Infection. 1996;24(2):136–139. doi:10.1007/BF01713319.
8. Goins RA, Ascher D, Waecker N, Arnold J, Moorefield E. Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants. Pediatr Infect Dis J. 2002;21(12):1165–1167. doi:10.1097/00006454-200212000-00017.
9. Pankhurst CL. Candidiasis (oropharyngeal). BMJ Clin Evid. 2012;2012:1304. PMID: 22348417. https://pmc.ncbi.nlm.nih.gov/articles/PMC4429411/
10. Médecins Sans Frontières. Oral and Oropharyngeal Candidiasis. MSF Medical Guidelines, 2025. https://medicalguidelines.msf.org/sites/default/files/2025-07/guideline-170-en.pdf
11. Canadian Paediatric Society. Antifungal Agents for Common Outpatient Paediatric Infections. Posted June 20, 2019; reaffirmed November 21, 2024. https://cps.ca/en/documents/position/antifungal-agents-common-infections
12. Te Whatu Ora Waikato. Candida Infections and Antifungal Treatment in the Newborn Unit. Guideline, version 02; February 23, 2024. https://healthshare.health.nz/file/2319/download?token=gQP3wXep
13. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–e50. doi:10.1093/cid/civ933.
14. Dermitzaki N, Baltogianni M, Tsekoura E, Giapros V. Invasive Candida Infections in Neonatal Intensive Care Units: Risk Factors and New Insights in Prevention. Pathogens. 2024;13(8):660. doi:10.3390/pathogens13080660.
15. European Medicines Agency. Propylene Glycol Used as an Excipient: Report Published in Support of Questions and Answers on Propylene Glycol Used as an

Journal of Advances in Drug Research

ISSN: 2230-7761
www.jadr.co.in

Volume 17, Issue 05 | Received 29.10.2026 | Accepted 3.11.2026 | Online 8.11.2026

Excipient in Medicinal Products for Human Use. 2017. https://www.ema.europa.eu/en/documents/report/propylene-glycol-used-excipient-report-published-support-questions-and-answers-propylene-glycol-used-excipient-medicinal-products-human-use_en.pdf

16. National Institutes of Health. Candida Infections: Guidelines for Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. Updated December 22, 2025. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/candida-infections
17. Nurdiana, Naorungroj S, Sappayatosok K, Lomlim L, Pahumunto N. Efficacy of botanical antifungal and conventional antifungal in the treatment of oral candidiasis: a systematic review and meta-analysis. Front Pharmacol. 2025;16:1635482. doi:10.3389/fphar.2025.1635482.
18. Médecins Sans Frontières. Miconazole Oral Gel: Essential Drugs Guidance. MSF Medical Guidelines. https://medicalguidelines.msf.org/en/viewport/EssDr/english/miconazole-oral-gel-16684167.html